Cordycepin inhibits chondrocyte hypertrophy of mesenchymal stem cells through PI3K/Bapx1 and Notch signaling pathway

Zhen Cao1,2, Ce Dou2, Jianmei Li2, Xiangyu Tang2, Junyu Xiang2, Chunrong Zhao2, Lingyu Zhu2, Yun Bai2, Qiang Xiang3 & Shiwu Dong2,*

1Department of Anatomy, Third Military Medical University, 2National & Regional United Engineering Laboratory of Tissue Engineering, Department of Biomedical Materials Science, School of Biomedical Engineering, Third Military Medical University, 3Department of Emergency, Southwest Hospital, Third Military Medical University, Chongqing 400038, China

Mesenchymal stem cells (MSCs) are widely used in cartilage tissue engineering to repair articular cartilage defects. However, hypertrophy of chondrocytes derived from MSCs might hinder the stabilization of hyaline cartilage. Thus, it is very important to find a suitable way to maintain the chondrogenic phenotype of chondrocytes. It has been reported that cordycepin has anti-inflammatory and anti-tumor functions. However, the role of cordycepin in chondrocyte hypertrophy remains unclear. Therefore, the objective of this study was to determine the effect of cordycepin on chondrogenesis and chondrocyte hypertrophy in MSCs and ATDC5 cells. Cordycepin up-regulated chondrogenic markers including Sox9 and collagen type II while down-regulated hypertrophic markers including Runx2 and collagen type X. Further exploration showed that cordycepin promoted chondrogenesis through inhibiting Nrf2 while activating BMP signaling. Besides, cordycepin suppressed chondrocyte hypertrophy through PI3K/Bapx1 pathway and Notch signaling. Our results indicated cordycepin had the potential to maintain chondrocyte phenotype and reconstruct engineered cartilage. [BMB Reports 2016; 49(10): 548-553]

INTRODUCTION

Acute cartilage defects may be caused by a comminuted or displaced intra-articular fracture. However, a chronic articular cartilage defect is often caused by matrix degradation during the progression of osteoarthritis (1-3). Limited by the intrinsic repairing capacity of cartilage tissue, repairing damaged articular cartilage currently faces major obstacles (4). Tissue engineering techniques have provided novel ways to repair cartilage defects (5). Mesenchymal stem cells (MSCs) have the potential of differentiation into chondrocytes. They are considered as appropriate seed cells in constructing cartilage through tissue engineering (6). The phenotype of chondrocyte derived from MSCs is difficult to maintain in cartilage reconstruction (7). Repair cells often lose chondrogenic activity which results in chondrocyte hypertrophy that can affect the formation of stable hyaline cartilage. Therefore, inhibiting chondrocyte hypertrophy in engineered cartilage is an enormous challenge (8).

Cordycepin, a nucleoside adenosine, is an effective substance of cordyceps (9). It has been reported that cordycepin possesses various biological functions, including antioxidant, hypolipidemic, and anti-inflammatory activities (10, 11). A recent study has confirmed that cordycepin may induce Leydig tumor cells apoptosis via MAPK/P38 signaling (12). However, the role of cordycepin in cartilage reconstruction, especially in chondrocyte hypertrophy, remains unclear. Therefore, the objective of this study was to determine the effect of cordycepin on chondrogenesis and chondrocyte hypertrophy in MSCs and ATDC5 cells. Specifically, we determined whether cordycepin could promote chondrogenesis of MSCs. We also determined whether cordycepin could affect chondrocyte hypertrophy of MSCs and murine chondroprogenitor cell line ATDC5 cells at early stage and late stage (13). Additional, several crucial genes of signaling pathway and transcription factors were examined to explore the molecular mechanisms involved in the effect of cordycepin on chondrocyte hypertrophy.

RESULTS

Cordycepin promotes chondrogenesis of MSCs

MSCs were cultured with basal culture medium for 24, 48, or 72 h and treated with different concentrations of cordycepin followed by CCK8 assays. Results showed that the concentration of cordycepin lower than 1 μg/ml had slight effect (P > 0.05) on cell proliferation (Fig. S1A, S1C, S1E). Therefore, cordycepin concentration of 1 μg/ml was regarded as safe and used in this study. After induction by chondrogenic
medium containing TGF-β3 together with cordycepin for 14 d, compared to control group Toluidine blue staining intensity was increased (P < 0.05) following cordycepin treatment on day 14 (Fig. S2C). Quantitative PCR (qPCR) analysis revealed that the mRNA levels of chondrogenesis markers including Sox9, Col II, COMP, and Acan in MSCs treated with cordycepin were significantly increased (P < 0.05) compared to group without cordycepin (Fig. 1D, S2B). After treatment with cordycepin, Sox9 protein level was increased on day 14 and Col II expression was increased on day 7 and 14 (Fig. 1B, S2E). Immunohistochemistry results also revealed that the expression levels of Sox9 and Col II were increased on day 7 and 14 based on the increases of integrated optical densities (Fig. 1C, S2A and S2D). Our data demonstrated that cordycepin promoted chondrogenesis at concentration of 1 μg/ml.

Cordycepin inhibits chondrocyte hypertrophy of MSCs at late stage

After induction with chondrogenic differentiation medium containing TGF-β3 for 14 d without cordycepin, MSCs were induced by hypertrophic medium containing T3 with cordycepin for another 14 d to examine the effect of cordycepin on chondrocyte hypertrophy. Cordycepin was used at concentration of 1 μg/ml. Toluidine blue staining showed that groups treated with cordycepin had higher (P < 0.05) intensity than control groups (Fig. 2A, 2C). Results of qPCR revealed, after cordycepin treatment, the expression levels of hypertrophic marker Col X in groups treated with cordycepin were increased (P < 0.05) on day 17 and 21, MMP13 levels were increased (P < 0.05) only on day 17, Runx2 levels were increased (P < 0.05) only on day 21, whereas the expression levels of MMP13 and Runx2 were decreased (P < 0.05) on day 28 compared with those in the control groups (Fig. 2D). Western blot analysis revealed that the protein levels of Col X and Runx2 in groups treated with cordycepin were not changed on day 17 but decreased on day 21 and 28 compared to those in the control groups (Fig. 2B, S3B). Immunohistochemistry results revealed that the expression levels of Col X and Runx2 in groups treated with cordycepin on day 21 and 28 were lower than those in the control groups based on integrated optical densities (Fig. S3A, S3C). These results demonstrated that cordycepin promoted chondrocyte hypertrophy of MSCs at early stage but inhibited chondrocyte hypertrophy of MSCs at late stage.

Cordycepin inhibits chondrocyte hypertrophy of ATDC5 cells at late stage

CCK8 assay was performed to examine the toxicity of cordycepin to ATDC5 cells. Concentration of cordycepin lower than 1 μg/ml had no significant (P > 0.05) effect on cell viability (Fig. S1B, S1D, and S1F). Therefore, cordycepin was used at 1 μg/ml for the following experiments to avoid toxicity issue. Previous results showed that cordycepin inhibited MSCs chondrocyte hypertrophy. As a useful tool to study the differentiation of chondrocytes, ATDC5 cells were induced by hypertrophic medium containing T3 with cordycepin for 14 d to examine the effect of cordycepin on chondrocyte hypertrophy. After treatment with cordycepin, compared to control group Toluidine blue staining intensity was increased (P < 0.05) on day 14 (Fig. S4A). Results of qPCR revealed that the mRNA levels of hypertrophic markers including MMP13 and Runx2 were increased (P < 0.05) in cells treated with cordycepin on day 3 but decreased (P < 0.05) on day 7 and 14 compared to group without cordycepin treatment (Fig. S4D). After treatment with cordycepin, Runx2 protein level was not changed (P > 0.05) on day 3 but decreased (P < 0.05) on day 7 and 14 compared to group without cordycepin treatment. Col X protein levels in cells treated with cordycepin were increased (P < 0.05) on day 3 but decreased (P < 0.05) on day 14 compared to group without cordycepin treatment (Fig. S4E, S4F). Immunohistochemistry results revealed that the
expression levels of Col X and Runx2 in cells treated with cordycepin on day 7 and 14 were lower than those in control groups without cordycepin treatment based on integrated optical densities (Fig. S4B, S4C). Taken together, these results demonstrated that ATDC5 cells hypertrophy were promoted by cordycepin at early stage but inhibited at late stage.

Cordycepin up-regulates BMP signaling during chondrogenesis and down-regulates Notch signaling during hypertrophy differentiation

To explore the molecular mechanisms involved in the effect of cordycepin on TGF-β3 induced chondrogenesis of MSCs, we performed qPCR and determined the expression levels of transcriptional factors and key molecules in canonical pathways related to chondrogenesis. After treatment with cordycepin, Hey1 expression was increased on day 3 and 14 compared to that in control groups. Expression levels of Id1 and Id3 were not changed by the treatment of cordycepin. However, Id2 expression was increased in treatment groups on day 14 compared to that in control groups. Moreover, the expression of PI3K was increased in the presence of cordycepin on day 3 and 7 whereas Nrf2 expression was decreased following cordycepin treatment on day 3, 7, and 14 (Fig. 3A). These results demonstrated that cordycepin promoted MSCs chondrogenesis through activating BMP and Notch signaling pathways. Besides, cordycepin up-regulated PI3K expression but down-regulated Nrf2 expression to facilitate MSCs chondrogenesis.

To further explore the molecular mechanisms, we performed qPCR to screen the expression of transcriptional factors and key molecules in canonical pathways associated with chondrocyte hypertrophy. In MSCs groups treated with cordycepin, the expression of β-catenin was increased on day 17 but unchanged on day 21 and day 28. Bapx1 expression was increased on day 28. On the contrary, the expression of PI3K was decreased on day 28. The expression levels of Hey1 and Hes5 (downstream genes in Notch signaling) were decreased on day 28. Hey1 expression was decreased on both day 21 and day 28 compared to that in the control groups (Fig. 3B, S5A). These results were similar to those obtained in ATDC5 cells. After treatment with cordycepin, the expression level of β-catenin was increased on day 3 but unchanged on day 7 or 14 compared to that in the control groups. Besides, after cordycepin treatment, Hes1 expression was decreased on day 3, 7, and 14, Hes5 expression was decreased on day 7 and 14, and Hey1 expression was decreased only on day 7. The expression of FAK (a positive regulator of chondrocyte hypertrophy) was increased following cordycepin treatment on day 3 but decreased on day 7 and 14. PI3K was the downstream signaling molecule of FAK. Its expression change was consistent with that of FAK (Fig. 3C, S5B). Taken together, these results indicated that cordycepin up-regulated BMP signaling during chondrogenesis but down-regulated Notch signaling during hypertrophy differentiation.

DISCUSSION

Cordycepin has been considered as an effective antioxidative agent with protective effects on respiratory system (14), nervous system (15), endocrine system (16), and tumor metastasis (12, 17, 18). Based on the characteristics of cordycepin, we hypothesized that cordycepin might also have effect on cartilage metabolism. A previous study has shown that cordycepin has protection against inflammatory cytokine inhibition of osteogenic differentiation of human adipose-derived mesenchymal stem cells (19). A recent study has also demonstrated that cordycepin could prevent oxidative stress-induced inhibition of osteogenesis (20).

In this study, we revealed that cordycepin had positive effect on TGF-β3 induced chondrogenesis of MSCs. Several specific genes related to cartilage such as Sox9 and Col II (21, 22) were examined in this study to explain the phenomenon at molecular level. These genes were up-regulated by cordycepin treatment. We then focused on two important signaling pathways during chondrogenesis: Notch and BMP. Notch signaling in MSCs is necessary for the initiation of chondrogenesis (23, 24). Besides, inhibitor of DNA binding/differentiation 1 (Id1), Id2, and Id3 are involved in the BMP signaling pathway indispensable for the formation of cartilage following the activation of the Col II gene (25-27). Our qPCR results showed that cordycepin could promote Notch signaling pathway during chondrogenesis. However, cordycepin started to show positive effect on BMP signaling pathway on day 14. In other words, BMP signaling was involved in the regulation of cordycepin at late stages of chondrogenic differentiation. During differentiation of MSCs into chondrocytes, the activation of PI3K can positively regulate chondrogenesis (28-30). Nrf2 negatively regulates cellular...
Cordycepin inhibits chondrocyte hypertrophy
Zhen Cao, et al.

Cordycepin inhibits chondrocyte hypertrophy and chondrogenesis through PI3K/Bapx1 pathway and Notch signaling. Besides, cordycepin suppresses chondrocyte hypertrophy through inhibiting Nrf2 and activating BMP signaling. Therefore, FAK could be a positive regulator of chondrocyte hypertrophy. In MSCs, cordycepin promoted chondrocyte hypertrophy through Wnt signaling and inhibited chondrocyte hypertrophy through Notch signaling. The expression of PI3K was decreased following cordycepin treatment on day 28 whereas the expression of Bapx1 was increased.

**MATERIALS AND METHODS**

**Cell culture**
C3H10T1/2 mesenchymal stem cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). ATDC5 cells were obtained from RIKEN cell Bank (Tsukuba, Japan). These cells were cultured in DMEM-F12 medium (Gibco) at 37°C with 5% CO2. The culture medium was refreshed every 3 d.

**Chondrogenic differentiation assay**
C3H10T1/2 cells and ATDC5 cells were seeded (2 × 10³ cells per well) into 96-well plates in triplicates and allowed to adhere overnight. On the following day, the medium was replaced by fresh medium containing cordycepin (Sigma-Aldrich Company). Cultures were incubated for 24, 48, or 72 hours. To determine cell viabilities, 10-μl of Cell Counting Kit-8 (CCK8, Dojindo Laboratories) reagent was added to each well and incubated for an additional 4 hours. The absorbance was read at wavelength of 450 nm on an automated plate reader. Wells containing CCK8 reagent without cells were used as blank controls. Cell proliferation was assessed based on the absorbance values according to the manufacturer’s protocol.

**Chondrogenic differentiation assay**
C3H10T1/2 cells were dissociated using 0.25% trypsin and adjusted to a density of 10⁵ cells/ml. Cell suspension (2 ml/well) was placed into the center of each well on a 6-well plate. After incubation for 24 h at 37°C with 5% CO2, the medium was replaced by 2 ml chondrogenic differentiation medium (Gibco) containing dexamethasone (100 nmol/L), ascorbate (50 μg/ml), ITS+ Supplement, proline (40 μg/ml), and TGF-β3 (10 ng/ml). The chondrogenic differentiation medium was refreshed every 3 d.

---

**Fig. 4.** Schematic diagram of cordycepin function in chondrogenesis and chondrocyte hypertrophy of MSCs. Cordycepin promotes chondrogenesis through inhibiting Nrf2 and activating BMP signaling. Besides, cordycepin suppresses chondrocyte hypertrophy through PI3K/Bapx1 pathway and Notch signaling.
Hypertrophic differentiation assay
ATDC5 cells were dissociated with 0.25% trypsin and adjusted to a density of 10^5 cells/ml. Cell suspension was placed into the center of each well on a 6-well plate (2 ml/well). After incubation at 37°C with 5% CO_2 for 24 h, the medium was replaced by 2 ml hypertrophic differentiation medium (Gibco) containing dexamethasone (1 nmol/L), ascorbate (50 μg/ml), ITS+Supplement, prolmine (40 μg/ml), and triiodothyronine (T3, 100 ng/ml). The hypertrophic differentiation medium was refreshed every 3 d.

Quantitative PCR (qPCR) analysis
Total RNA was isolated from cells using Trizol reagent (Life Technologies). Single-stranded cDNA was prepared from 1 μg of total RNA using reverse transcriptase and oligo-dT primer according the manufacturer’s instructions. Each cDNA (2 μl) was subjected to qPCR amplification using gene specific primers (Table S1). The cycling conditions were set as 95°C for 30 seconds, 40 cycles of 95°C for 5 seconds, and 60°C for 30 seconds. The relative mRNA level was calculated by the normalization to that of GAPDH (39).

Western blot analysis
Cells were extracted with cell lysis buffer [50 mM Tris (pH 7.6), 150 mM NaCl, 1% TritonX-100, 1% deoxycholate, 0.1% SDS, 1 mM PMSF, and 0.2% Aprotinin (Beyotime)]. After measuring protein concentration by BCA protein assay (Beyotime), equal protein amounts were mixed with 5× sample buffer (Beyotime) and boiled. These samples were resolved on 10% SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) and transferred onto PVDF (polyvinylidene fluoride) membrane by using semi-dry transfer method. After blocking in 10% nonfat dry milk in TBST (tris-buffered saline tween-20) for 2 h, blots were incubated with primary antibodies including Col II (rabbit polyclonal 1:500, Abcam), Sox9 (rabbit polyclonal 1:500, Abcam), Runx2 (rabbit polyclonal 1:500, Abcam) and Col X (rabbit polyclonal 1:500, Abcam) at 4°C overnight. After washing with PBS, cells were incubated with biotinylated goat anti-rabbit (ZSGB-BIO) secondary antibodies for 30 min followed by washing and incubation with horseradish peroxidase (HRP) conjugated secondary antibody (ZSGB-BIO) for 15 min. The area of the immunocomplex was visualized using chromogen 3, 3’-diaminobenzidine (DAB) as substrate for 5 min. Cells were observed under Olympus fluorescence microscope (IX71). Image-Pro plus 6.0 software was used for image analysis.

Immunohistochemistry
Cells were fixed in 4% paraformaldehyde for 15 min, washed in phosphate-buffered saline (PBS), and treated with H_2O_2 (ZSGB-BIO Biotech, Beijing, China) for 10 min to inactivate endogenous peroxidase. After treatment with normal goat serum (ZSGB-BIO) at room temperature for 15 min, cells were incubated with primary antibody including Col II (rabbit polyclonal 1:500, Abcam), Sox9 (rabbit polyclonal 1:500, Abcam), Runx2 (rabbit polyclonal 1:500, Abcam) and Col X (rabbit polyclonal 1:500, Abcam) at 4°C overnight. After washing with PBS, cells were incubated with biotinylated goat anti-rabbit (ZSGB-BIO) secondary antibodies for 30 min followed by washing and incubation with horseradish peroxidase (HRP) conjugated secondary antibody (ZSGB-BIO) for 15 min. The area of the immunocomplex was visualized using chromogen 3, 3’-diaminobenzidine (DAB) as substrate for 5 min. Cells were observed under Olympus fluorescence microscope (IX71). Image-Pro plus 6.0 software was used for image analysis.

REFERENCES
1. Madry H and Cucchiarini M (2014) Tissue-engineering strategies to repair joint tissue in osteoarthritis: nonviral gene-transfer approaches. Curr Rheumatol Rep 16, 450
2. Mardones R, Jofre CM and Minguell JJ (2015) Cell Therapy and Tissue Engineering Approaches for Cartilage Repair and/or Regeneration. Int J Stem Cells 8, 48-53
3. Caldwell KL and Wang J (2015) Cell-based articular cartilage repair: the link between development and regeneration. Osteoarthritis Cartilage 23, 351-362
4. He B, Yuan X, Zhou A, Zhang H and Jiang D (2014) Designer functionalised self-assembling peptide nanofibre scaffolds for cartilage tissue engineering. Expert Rev Mol Med 16, e12
5. Sun AX, Lin H, Beck AM, Kilroy EJ and Tuan RS (2015) Projection Stereolithographic Fabrication of Human Adipose Stem Cell-Incorporated Biodegradable Scaffolds for Cartilage Tissue Engineering. Front Bioeng Biotechnol 3, 115
6. Bradamante S, Barenghi L and Maier JA (2014) Stem Cells toward the Future: The Space Challenge. Life (Basel) 4,
Cordycepin inhibits chondrocyte hypertrophy
Zhen Cao, et al.

267-280

7. Kaul G, Cucchiari M, Remberger K, Kohn D and Madry H (2012) Failed cartilage repair for early osteoarthritis defects: a biochemical, histological and immunohistochemical analysis of the repair tissue after treatment with marrow-stimulation techniques. Knee Surg Sports Traumatol Arthrosc 20, 2315-2324

8. Sun MM and Beier F (2014) Chondrocyte hypertrophy in skeletal development, growth, and disease. Birth Defects Res C Embryo Today 102, 74-82

9. Nakamura K, Shinozuka K and Yoshikawa N (2015) Anticancer and antimitotic effects of cordycepin, an active component of Cordyceps sinensis. J Pharmacol Sci 127, 53-56

10. Tuli HS, Sharma AK, Sandhu SS and Kashyap D (2013) Cordycepin: a bioactive metabolite with therapeutic potential. Life Sci 93, 863-869

11. Yue K, Ye M, Zhou Z, Sun W and Lin X (2013) The genus Cordyceps: a chemical and pharmacological review. J Pharm Pharmacol 65, 474-493

12. Pan BS, Wang YK, Lai MS, Mu YF and Huang BM (2015) Cordycepin induced MA-10 mouse Leydig tumor cell apoptosis by regulating p38 MAPKs and PI3K/AKT signaling pathways. Sci Rep 5, 13372

13. Yao Y and Wang Y (2013) ATDC5: an excellent in vitro model cell line for skeletal development. J Cell Biochem 114, 1223-1229

14. Yang X, Li Y, He Y et al (2015) Cordycepin alleviates airway hyperreactivity in a murine model of asthma by attenuating the inflammatory process. Int Immunopharmacol 26, 401-408

15. Peng J, Wang P, Ge H, Qu X and Jin X (2015) Effects of cordycepin on the microglia-overflowactivation-induced impairments of growth and development of hippocampal cultured neurons. PLoS One 10, e0125902

16. Ma L, Zhang S and Du M (2015) Cordycepin from Cordyceps militaris prevents hyperglycemia in alloxan-induced diabetic mice. Nutr Res 35, 431-439

17. Kang FC, Chen PJ, Pan BS, Lai MS, Chen YC and Huang BM (2015) Apoptotic effect of cordycepin combined with cisplatin and/or paclitaxel on MA-10 mouse Leydig tumor cells. Onco Targets Ther 9, 2541-2547

18. Li Z, Lu H and Li ZB (2014) The PI3K/Akt signaling pathway may play an internal role related to abnormal condylar growth: a preliminary study. Int J Oral Maxillofac Surg 43, 1477-1483

19. Hinoi E, Takarada T, Fujimori S et al (2007) Nuclear factor-κB (NF-κB) signaling triggers Nkx3.2 protein degradation during chondrogenesis of human bone marrow stromal cells. Bone 40, 337-344

20. Choi SW, Jeong DU, Kim JA et al (2012) Indian Hedgehog signalling triggers Nkx3.2 protein degradation during chondrocyte maturation. Biochem J 443, 789-798

21. Kohn A, Dong Y, Miranda AJ et al (2012) Cartilage-specific RBPs/Kappa-dependent and -independent Notch signals regulate cartilage and bone development. Development 139, 1198-1212

22. Caron MM, Emans PJ, Cremers A et al (2013) Hypertrophic differentiation during chondrogenic differentiation of progenitor cells is stimulated by BMP-2 but suppressed by BMP-7. Osteoarthritides Cartilage 21, 604-613

23. Oldershaw RA and Hardingham TE (2010) Notch signaling during chondrogenesis of human bone marrow stem cells. Bone 46, 286-293

24. Ma Y, Bian J and Zhang F (2015) Inhibition of perillyl alcohol on cell invasion and migration depends on the Notch signaling pathway in hepatoma cells. Mol Cell Biochem 411, 307-315

25. Karystinou A, Roelofs AJ, Neve A, Cantatore FP, Wackerhage H and De Bari C (2015) Yes-associated protein (YAP) is a negative regulator of chondrogenesis in mesenchymal stem cells. Arthritis Res Ther 17, 147

26. Long F and Ornitz DM (2013) Development of the endochondral skeleton. Cold Spring Harb Perspect Biol 5, a008334

27. Dong J, Lei X, Wang Y et al (2015) Different Degrees of Iodine Deficiency Inhibit Differentiation of Cerebellar Granular Cells in Rat Offspring, via BMP-Smad1/5/8 Signaling. Mol Neurobiol 53, 4606-4617

28. Shang J, Liu H, Li J and Zhou Y (2014) Roles of hypoxia during the chondrogenic differentiation of mesenchymal stem cells. Curr Stem Cell Res Ther 9, 141-147

29. Mitsugi S, Ariyoshi W, Okinaga T et al (2012) Mechanisms involved in inhibition of chondrogenesis by activin-A. Biochem Biophys Res Commun 420, 380-384

30. Thamilselvan V, Craig DH and Basson MD (2007) FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway. FASEB J 21, 1730-1741

31. Cheng K, Xia P, Lin Q et al (2014) Effects of low-intensity pulsed ultrasound on integrin-FAK/PI3K/Akt mechanochemical transduction in rabbit osteoarthritides chondrocytes. Ultrasound Med Biol 40, 1609-1618

32. Chen S, Fu P, Cong R, Wu H and Pei M (2015) Strategies to minimize hypertrophy in cartilage engineering and regeneration. Genes Dis 2, 76-95

33. Bustin SA, Benes V, Nolan T and Pfaffl MW (2005) Quantitative real-time RT-PCR—a perspective. J Mol Endocrinol 34, 597-601